Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1Phase 1/2 1

Status

Completed 44Terminated 19Active not recruiting 16Unknown 6Withdrawn 5Recruiting 3Not yet recruiting 1

Sponsor Class

OTHER 5INDUSTRY 3NIH 2

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2Sarcoma 1Other hematologic neoplasm 1

Conditions

Recurrence 2Multiple Myeloma 2Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neurofibrosarcoma 1Neoplasms 1Lymphoma 1Liposarcoma 1Leukemia, Biphenotypic, Acute 1

Interventions

Radiotherapy 91pembrolizumab 88Cyclophosphamide 84Gemcitabine 70Cisplatin 70Magnetic Resonance Spectroscopy 65Carboplatin 60Radiosurgery 55Paclitaxel 55Nivolumab 48Dexamethasone 45Bevacizumab 42Biopsy 41Fluorouracil 39durvalumab 37Surveys and Questionnaires 36Docetaxel 36fludarabine 35Doxorubicin 35Radiation 33Oxaliplatin 33Capecitabine 33Rituximab 32fludarabine phosphate 31Leucovorin 31Cytarabine 30Melphalan 29Etoposide 28Pemetrexed 27Irinotecan 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Withdrawn × OTHER × ixazomib × Clear all
NCT06050512 2024-11-19

Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma

University of Pittsburgh

Phase 1/2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence

NCT03880123 2020-11-27

Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma

Columbia University

Phase 1 Withdrawn
Sarcoma

Liposarcoma, Sarcoma, Sarcoma, Ewing, Sarcoma, Alveolar Soft Part, Neurofibrosarcoma

NCT02578511 2018-02-15

Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)

Medical College of Wisconsin

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03422874 2018-02-06

Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma

Dartmouth-Hitchcock Medical Center

Phase 1 Withdrawn
Lymphoid

Lymphoma, Neoplasms

NCT02578121 2017-01-23

UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination

University of Arkansas

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡